CV - European Medicines Agency
Transcrição
CV - European Medicines Agency
Curriculum Vitae PERSONAL INFORMATION Keikawus Arastéh WORK EXPERIENCE 2011–Present Medical Director Vivantes Auguste-Viktoria-Klinikum Vivantes Auguste-Viktoria-Klinikum, (Germany) 2001–Present Director of the Department of Internal Medicine, Gastroenterology and Infectious Diseases Vivantes Auguste-Viktoria-Klinikum, (Germany) 2000–2000 Deputy Chief Physician of the Department of Internal Medicine, Gastroenterology and Infectious Diseases Vivantes Auguste-Viktoria-Klinikum, (Germany) 1998–Present CEO and Principal Investigator EPIMED - Gesellschaft für epidemiologische und klinische Forschung in der Medizin mbH, (Germany) 1992–December 1999 Chief Senior Physician of the Immunological Dayclinic, Department of Internal Medicine, Gastroenterology and Infectious Diseases Auguste-Viktoria-Klinikum, (Germany) 1983–1992 Assistant Physician of the Department of Internal Medicine, Gastroenterology and Infectious Diseases Auguste-Viktoria-Klinikum, (Germany) EDUCATION AND TRAINING November 2013–Present Approval as Specialist in Gastroenterology Ärztekammer Berlin, (Germany) 2006–Present Approval as Specialist in Infectious Diseases Ärztekammer Berlin, (Germany) 2005–Present Approval as Fellow in Gastroenterology European Board of Gastroenterology (EBG) 2003–Present Approval as Specialist in Infectious Diseases Deutsche Gesellschaft für Infektiologie, (Germany) 2000–Present Habilitation/ Privatdozent Freie Universität, Berlin, (Germany) 1991–Present Completion of medical thesis, (PhD / Dr. med.) Freie Universität, Berlin, (Germany) 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 1 / 7 Curriculum Vitae 1990–Present 1976–1983 Keikawus Arastéh Approval as Specialist in Internal Medicine Medical Studies Freie Universität Berlin, (Germany) ADDITIONAL INFORMATION Expertise Internal Medicine, Infectious Diseases, Gastroenterology Principal Investigator of Medical Trials (HIV and Hepatitis) Publications ► Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist. 2000;5 Suppl 1:28-31. ► Arasteh KN, Cordes C, Ewers M, Simon V, Dietz E, Futh UM, Brockmeyer NH, L'Age M P. HIVrelated nontuberculous mycobacterial infection: incidence, survival analysis and associated risk factors. Eur J Med Res. Oct 30 2000;5(10):424-430. ► Arasteh K, Muller M. [New antiretroviral drugs. Improved pharmacokinetics and simpler dose schedules]. MMW Fortschr Med. Apr 2 2001;143 Suppl 1:14-17. ► Arasteh K, Wood R, Muller M, Prince W, Cass L, Moore KH, Dallow N, Jones A, Klein A, Burt V, Kleim JP. GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine. HIV Clin Trials. Jul-Aug 2001;2(4):307-316. ► Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A, Schranz D, Moecklinghoff C, Arasteh K. Predictors of treatment failure during highly active antiretroviral therapy (racing trial). Eur J Med Res. Aug 30 2002;7(8):341-346. ► Arasteh K, Muller M. [Improving resistance profile, simplifying administration mode. New antiretroviral drugs]. MMW Fortschr Med. Apr 9 2002;144 Suppl 1:66-70. ► Arasteh K. Denying history. Am Psychol. Apr 2004;59(3):182. ► Herzmann C, Duesberg U, Arasteh K. [New therapeutic strategies in HIV infection-immune reconstitution and virus suppression]. Med Klin (Munich). Jun 15 2004;99(6):323-325. ► Arasteh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. Jun 10 2005;19(9):943-947. ► Arasteh K, Muller M. [New drugs--hope for salvage patients?]. MMW Fortschr Med. Apr 25 2005;147 Spec No 1:38-41. ► Arasteh K, Stocker H. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors. Eur J Med Res. Oct 15 2007;12(9):397-402. ► Traeder C, Kowoll S, Arasteh K. Candida infection in HIV positive patients 1985-2007. Mycoses. Sep 2008;51 Suppl 2:58-61. ► Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS. Jan 14 2009;23(2):274-275. ► Arasteh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Bethune MP, Peeters M, Woodfall B. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther. 2009;14(5):713-722. ► Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg R, Mertenskoetter T. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). Eur J Med Res. May 14 2009;14(5):195-199. ► Arasteh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859-864. ► Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jager H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. Sep 29 2011;118(13):3499-3503. 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 2 / 7 Curriculum Vitae Keikawus Arastéh ► Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P, Quinson A. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med. Apr 2012;13(4):236-244. Co-Author ► Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS. May 5 2000;14(7):781-789. ► Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med. Jan 2001;2(1):27-34. ► Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA. An open-label assessment of TMC 125--a new, nextgeneration NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. Dec 5 2003;17(18):F49-54. ► Kreuter A, Reimann G, Esser S, Rasokat H, Hartmann M, Swoboda J, Conant MA, Tschachler E, Arasteh K, Altmeyer P, Brockmeyer NH. [Screening and therapy of anal intraepithelial neoplasia (AIN) and anal carcinoma in patients with HIV-infection]. Dtsch Med Wochenschr. Sep 19 2003;128(38):1957-1962. ► Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. May 29 2003;348(22):2186-2195. ► Dunay IR, Heimesaat MM, Bushrab FN, Muller RH, Stocker H, Arasteh K, Kurowski M, Fitzner R, Borner K, Liesenfeld O. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother. Dec 2004;48(12):4848-4854. ► Salzberger B, Marcus U, Vielhaber B, Arasteh K, Golz J, Brockmeyer NH, Rockstroh J. GermanAustrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res. Nov 29 2004;9(11):491-504. ► Scheller C, Ullrich A, McPherson K, Hefele B, Knoferle J, Lamla S, Olbrich AR, Stocker H, Arasteh K, ter Meulen V, Rethwilm A, Koutsilieri E, Dittmer U. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem. May 21 2004;279(21):21897-21902. ► Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. Nov 2004;48(11):4148-4153. ► Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. Jan 2004;48(1):116-123. ► Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis. Aug 15 2004;39(4):591-594. ► Herzmann C, Arasteh K, Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A, Cartee L, Otto MJ. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virusinfected patients. Antimicrob Agents Chemother. Jul 2005;49(7):2828-2833. ► Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P. Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations. HIV Med. Mar 2005;6(2):107-113. ► Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss S, Rockstroh JK. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection. Jun 2005;33(3):140-147. 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 3 / 7 Curriculum Vitae Keikawus Arastéh ► Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. Dec 1 2005;40(4):404-412. ► Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Jr., Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. Dec 1 2005;40(4):413-421. ► Weitzel T, Muhlberger N, Jelinek T, Schunk M, Ehrhardt S, Bogdan C, Arasteh K, Schneider T, Kern WV, Fatkenheuer G, Boecken G, Zoller T, Probst M, Peters M, Weinke T, Gfrorer S, Klinker H, Holthoff-Stich ML. Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis. Jul 2005;24(7):471-476. ► Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, Lopez P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIVinfected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. Nov 15 2006;43(10):13471356. ► Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol. Jun 2006;17(6):914-919. ► Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin H, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arasteh K, Kurowski M. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother. Feb 2006;50(2):667-673. ► Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer. Apr 1 2006;106(7):1560-1568. ► Gathe JC, Jr., Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses. Feb 2007;23(2):216-223. ► Reynes J, Arasteh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, M OH, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. Aug 2007;21(8):533-543. ► Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739-756. ► Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmuller J, Becker M, Arasteh K, Kurowski M. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. J Antimicrob Chemother. Mar 2007;59(3):560-564. ► van Lunzen J, Liess H, Arasteh K, Walli R, Daut B, Schurmann D. Concomitant use of gastric acidreducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. May 2007;8(4):220-225. ► Kakuda TN, Scholler-Gyure M, Workman C, Arasteh K, Pozniak AL, De Smedt G, Beets G, Peeters M, Vandermeulen K, Woodfall BJ, Hoetelmans RM. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008;13(5):655-661. ► Schulbin H, Bode H, Stocker H, Schmidt W, Zippel T, Loddenkemper C, Engelmann E, Epple HJ, Arasteh K, Zeitz M, Ullrich R. Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy. Antimicrob Agents 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 4 / 7 Curriculum Vitae Keikawus Arastéh Chemother. Sep 2008;52(9):3377-3384. ► Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clin Ther. Sep 2011;33(9):13081320. ► Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arasteh K, Chung J, Rowell L, Guimaraes D, Bertasso A. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med. Jan 2011;12(1):31-39. ► Marretta L, Stocker H, Drauz D, Mueller M, Masuhr A, Dieckmann S, Wong V, Koch A, Grueneisen A, Arasteh K, Weiss R. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res. May 12 2011;16(5):197-205. ► Soriano V, Arasteh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviralnaive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16(3):339-348. ► von Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, Huisinga W. HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS One. 2011;6(3):e18204. ► Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. Dec 2011;141(6):2047-2055; quiz e2014. ► Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arasteh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Bocher W, Steffgen J. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol. Jul 2012;57(1):39-46. ► Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Fatkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schurmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. Nov 20 2012;30(33):4117-4123. ► Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. Aug 2012;13(7):406-415. ► Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, Dejesus E, Antunes F, Arasteh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK. Cobicistat versus ritonavir as a pharmacoenhancer for atazanavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients: Week 48 results. J Infect Dis. Mar 26 2013. ► Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatmentnaive HCV genotype 1: SOUND-C1 final results. Antivir Ther. Apr 4 2013. ► Jacobson, Asselah, Ferenci, Foster, Jensen, Negro, Mantry, Wright, Forns, Garcia-Samaniego, Oliveira, Carvalho, Forton, Arastéh, Cooper, Ghesquiere, Dufour, Sakai, Tanaka, Stern, Sha, Boecher, Steinmann, Quinson, on behalf of the STARTVerso3 Study Group. STARTVerso 3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection , American Association for the Study of the Liver: The Liver Meeting 2013. Poster Number 1100 ► Jürgen Kurt Rockstroh, Mark Nelson, Vicente Soriano, Keikawus Arastéh, Josep Guardiola, Sanjay Bhagani, Josep Mallolas, Cristina Tural, Massimo Puoti, Patrick Ingiliz, Manuel Battega, Mamta K. Jain, Marina Nunez, Kristen Marks, Jens Kort, Jerry Stern, Richard Vinisko, Montserrat Manero, Douglas Dieterich. STARTVerso 4 Phase III Trial of Faldaprevir Once-daily Plus Peg Interferon Alfa-2a and Ribavirin (PR) in Patients with HIV and HCV Genotype 1 Coinfection: End of Treatment Response (ETR) 14th European AIDS Conference (EACS), 16.-19. October 2013 ► Stellbrink, Hans-Jürgen; Arastéh, Keikawus; Schürmann, Dirk; Stephan, Christoph; Dierynck, Inge; Smyej, Ilham; Hoetelmans, Richard M. W.; Truyers, Carla; Meyvisch, Paul ; Jacquemyn, Bert; Mariën, 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 5 / 7 Curriculum Vitae Keikawus Arastéh Kris; Simmen, Kenneth; Verloes, René. Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected Patients JAIDS Journal of Acquired Immune Deficiency Syndromes:1 March 2014 - Volume 65 Issue 3 - p 283–289 ► Douglas Dieterich, Cristina Tural, Mark Nelson, Keikawus Arastéh, Vicente Soriano, Josep Guardiola, Sanjay Bhagani, Jürgen K Rockstroh, Jerry O Stern, Anne-Marie Quinson. Faldaprevir Plus Pegylated Interferon α-2a/Ribavirin in HIV/HCV Co-infection: STARTVerso4 The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014 ► Mark Nelson, Keikawus Arastéh, Mamta K Jain, Vicente Soriano, José Valdez Madruga, Juvencio Furtado, Manuel Battegay, Fenglei Huang, Montserrat Manero, Douglas Dieterich. Effect of Faldaprevir on Atazanavir Pharmacokinetics in Patients with HIV/HCV Co-Infection The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014 ► J. O. Morales-Ramirez, J. M. Gatell, D. P. Hagins, M. Thompson, K. Arasteh, C. Hoffmann, C. Harvey, X. Xu, H. Teppler . Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014 ► Douglas Dieterich, Peter Ferenci, Ira M Jacobson, Francesco Negro, Massimo Puoti5, Jürgen K Rockstroh, Michael P Manns, Keikawus Arastéh, Célia Oliveira, Jean-François Dufour, Elmar Zehnter, Clifford Leen, Sanjay Bhagani, Jerry O Stern, Anne-Marie Quinson, Joseph Scherer, Montserrat Manero, Donald M Jensen. SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENTNAÏVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9–13, 2014 Guidelines ► Arasteh K, Bader A, Berg T, Blauhut B, Bogner J, Brockhaus W, Brockmeyer N, Brodt H, Dalhoff K, Doerr H, Dupke S, Esser S, Fleckenstein B, Goebel F, Gölz J, Grosch-Wörner I, Gross G, Gürtler L, Hartmann H, Helm E, Hoffmann C, Jäger H, Jarke J, Jablonowski H, Junginger T, Kern P, Knechten H, Körner T, Korn K, Kramer A, Kräuslich H, Kurowski M, Lechl P, Lessy D, Marcus U, Mauss S, Moll A, Müller W, Pfeil B, Pistner H, Plettenberg A, Rasokat H, Reimann G, Remé T, Rieger A, Röcken M, Rockstroh J, Ruf B, Rump J, Salzberger B, Schafberger B, Schedel I, Schmied B, Schmidt R, Schramm W, Schrappe M, Shah P, Staszewski S, Stellbrink H, Stoehr A, Stoll M, Thoma-Greber E, Tschachler E, Überla K, Vetter N, Zangerle R. Deutsch-Österreichische Leitlinien zur postexpositionellen Prophylaxe der HIV-Infektion. Dtsch Med Wochenschr 2003,128:36-50. ► Arasteh K, Bader A, Berg T, Blauhut B, Bogner J, Brockhaus W, Brockmeyer N, Brodt H, Doerr H, Dupke S, Esser S, Fleckenstein B, Goebel F, Gölz J, Grosch-Wörner I, Gross G, Gürtler L, Hartmann H, Helm E, Hoffmann C, Jäger H, Jablonowski H, Kern P, Knechten H, Körner T, Korn K, Kramer A, Kräuslich H, Kurowski M, Marcus U, Moll A, Pfeil B, Plettenberg A, Rasokat H, Reimann G, Rieger A, Rockstroh J, Ruf B, Rump J, Salzberger B, Schafberger B, Schedel I, Schmied B, Schmidt B, Schmidt R, Shah P, Schöfer H, Schrappe M, Staszewski S, Stellbrink H, Stoehr A, Stocker H, Stoll M, Tschachler E, Überla K, Vetter N, Zangerle R. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV Infektion. Dtsch Med Wochenschr 2003,128:7-18. ► Salzberger B, Marcus U, Vielhaber B, Arasteh K, Golz J, Brockmeyer NH, Rockstroh J. German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res 2004,9:491-504. Books / Book Chapters ► Buchveröffentlichung als Autor (Rudolf Weiß und Keikawus Arastéh): „Buch gegen die Panik – Leben mit der HIV-Infektion“, 9 Auflagen, Erstausgabe 1994, 9. Auflage 2007 ► Mitautor Buchkapitel „HIV-Infektion und AIDS“ im Buch „Duale Reihe - Innere Medizin“ Thieme Verlag, 2. Auflage, 2009 Projects Memberships ► Active Member Expertenpanel „RADATA“ des Instituts für Interdisziplinäre Medizin (Expertenratsystem zur Optimierung antiretroviraler Therapieentscheidungen) ► Active Member Editorial Boards des Journals „BioMed Research Internaional”, Hindawi Publishing 19/1/15 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 6 / 7 Curriculum Vitae Keikawus Arastéh Corporation ► Active Member Editorial Boards des Journals „ISRN AIDS”, Hindawi Publishing Corporation ► Active Member Editorial Boards des Journals „Infection”, Springer Journals ► Active Member Editorial Boards des Journals „Journal of AIDS & Clinical Research”, Journal of AIDS & Clinical Research ► Active Member Editorial Boards des Journals „JOURNAL OF AIDS & ITS RESEARCH (IJAR)”, Nuclei Online publishing group ► Active Member Editorial Boards des Journals „BioMed Research Internaional”, Hindawi Publishing Corporation ► Active Member Editorial Boards des Journals „ISRN AIDS”, Hindawi Publishing Corporation ► Active Member Editorial Boards des Journals „Infection”, Springer Journals ► Active Member Editorial Boards des Journals „Journal of AIDS & Clinical Research”, Journal of AIDS & Clinical Research ► Active Member Editorial Boards des Journals „JOURNAL OF AIDS & ITS RESEARCH (IJAR)”, Nuclei Online publishing group Other Relevant Information 19/1/15 Gilead HIV Clinical Cooparation Grant for the project Clinical Research and Education with Donetsk Regional Center of AIDS Prevention and Control, UA, Juni 2007 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 7 / 7